Songtradr readies for $750m float; Meso blast’s $1b bonfire; Hopper debuts Radiopha rm Theranostics

Good evening,

Songtradr investors have a reason to be singing tonight. The online music rights management and licensing platform has turned up the volume on its IPO plans, enlisting investment banks Goldman Sachs and Jarden.

The company has told investors it is planning to go public on the ASX in the first half of 2022 and expects the business to be valued between $600 million and $750 million.

Songtradr was founded by former songwriter and record producer Paul Wiltshire in 2014 and WiseTech’s Richard White is its second-largest shareholder. White bought into the company’s $4 million series A raise and continued investing in its consequent rounds, including its latest $US50 million pre-IPO. Institutions Perennial, Regal Funds Management, Aware Super and Argo are also on its capital table.

Elsewhere: Ownership Matters has run the numbers on Mesoblast and its operating cash outflows are closing in on $1 billion, while it’s only generated $22 million in cash receipts; Viralytics’ Paul Hopper is back with a new biotech venture called Radiopharm Theranostics and he’s planning to list the business in November; Afterpay’s employee share schemes will roll into Square as part of the takeover; and the BNPL raisings post-Afterpay kick off with BizPay.

Happy reading,

Anthony Macdonald and Yolanda Redrup
Street Talk Editors